Good news and a nice precursor to hopefully positive news in the...

Good news and a nice precursor to hopefully positive news in the US..

For all predefined study endpoints, ResApp’s algorithms performed very well, achieving a positive percent agreement (PPA) between 79% and 97% and a negative percent agreement (NPA) between 80% and 91% when compared to a clinical diagnosis. The results for asthma/reactive airway disease (RAD) were exceptional, with a PPA of 97% and an NPA of 91%. Asthma/RAD diagnosis is typically performed in the clinic using an inhaled bronchodilator test, which is time consuming and costly. For pneumonia, a disease that is responsible for the death of more children under five than any other disease, ResApp’s algorithms delivered a PPA of 87% and an NPA of 85%. For lower respiratory tract disease, a key diagnosis for telehealth consultations in particular, ResApp’s algorithms yielded a PPA of 83% and an NPA of 82%. While a shortage of patients under two without bronchiolitis limited the statistical robustness of the study’s bronchiolitis results, the algorithm’s performance was again excellent with PPA and NPA both above 80%.